10 septiembre 2015
A multiple myeloma patient whose cancer had stopped responding after nine different treatment regimens experienced a complete remission after receiving an investigational personalized cellular therapy known as CTL019. The investigational treatment was combined with chemotherapy and an autologous stem cell transplant — a new strategy designed to target and kill the cells that give rise to myeloma cells.
http://www.sciencedaily.com/releases/2015/09/150909213412.htm
